Table 3. Phase III programme STAIR II criteria.
• Dose selection based on phase 1 and II data plasma concentrations |
• Time window for drug initiation |
• Patient selection based on mechanisms of action |
• Outcome measures |
• Severity of stroke population to be studied |
• Length of follow-up period |
• Use of surrogate markers to provide support for drug efficacy |
• Prespecification of covariate analysis |
• Fostering of appropriate and effective relationships between sponsors, academics and investigators |